A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer.
Zheng L, Edil BH, Soares KC, El-Shami K, Uram JN, Judkins C, Zhang Z, Onners B, Laheru D, Pardoll D, Jaffee EM, Schulick RD. A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer. Ann Surg Oncol. 2014 Nov; 21(12):3931-7.
-
Adenocarcinoma
-
Adenocarcinoma
-
Adult
-
Adult
-
Aged
-
Aged
-
Antineoplastic Agents, Alkylating
-
Antineoplastic Agents, Alkylating
-
Cancer Vaccines
-
Cancer Vaccines
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase I as Topic
-
Colorectal Neoplasms
-
Colorectal Neoplasms
-
Combined Modality Therapy
-
Combined Modality Therapy
-
Cyclophosphamide
-
Cyclophosphamide
-
Feasibility Studies
-
Feasibility Studies
-
Female
-
Female
-
Follow-Up Studies
-
Follow-Up Studies
-
Humans
-
Humans
-
Immunotherapy
-
Immunotherapy
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
-
Lymphatic Metastasis
-
Lymphatic Metastasis
-
Macrophage Colony-Stimulating Factor
-
Macrophage Colony-Stimulating Factor
-
Male
-
Male
-
Middle Aged
-
Middle Aged
-
Neoplasm Recurrence, Local
-
Neoplasm Recurrence, Local
-
Neoplasm Staging
-
Neoplasm Staging
-
Prognosis
-
Prognosis
-
Safety
-
Safety
-
Survival Rate
-
Survival Rate
-
Tumor Cells, Cultured
-
Tumor Cells, Cultured